IGC

IGC Pharma Inc

0.2715

Jun 30 • 09:35AM ET +0.0005 (0.18%)

Healthcare Biotechnology USA Nano AMEX

Peers: APLM BRNS CRVO GRDX LSTA NRSN PLRZ SER SKYE SNTI

Scroll to Statements

Index	-
Market Cap	27.17M
Enterprise Value	27.87M
Income	-5.34M
Sales	1.20M
Book/sh	0.06
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	70
IPO	Apr 13, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	22.64
P/B	4.38
P/C	118.13
P/FCF	-
EV/EBITDA	-
EV/Sales	23.23
Quick Ratio	0.17
Current Ratio	0.40
Debt/Eq	0.15
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-0.06
EPS next Y	-
EPS next Q	-0.02
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	32.33% 12.85%
Sales past 3/5Y	47.38% -20.77%
EPS Y/Y TTM	49.51%
Sales Y/Y TTM	-2.99%
EPS Q/Q	-65.54%
Sales Q/Q	-3.94%
Earnings	May 20 BMO
EPS/Sales Surpr.	- -

Insider Own	22.81%
Insider Trans	0.00%
Inst Own	4.25%
Inst Trans	-0.56%
ROA	-68.43%
ROE	-90.87%
ROIC	-84.65%
Gross Margin	3.00%
Oper. Margin	-763.72%
Profit Margin	-445.62%
SMA20	-2.55%
SMA50	-8.17%
SMA200	-14.34%
Trades

Shs Outstand	98.80M
Shs Float	77.26M
Short Float	0.27%
Short Ratio	0.17
Short Interest	0.21M
52W High	0.50 -45.54%
52W Low	0.24 12.19%
Volatility	6.03% 5.43%
ATR (14)	0.01
RSI (14)	43.00
Beta	0.46
Rel Volume	0.27
Avg Volume	1.24M
Volume	20,572

Perf Week	2.45%
Perf Month	-6.02%
Perf Quarter	6.26%
Perf Half Y	-9.47%
Perf YTD	-3.52%
Perf Year	-11.27%
Perf 3Y	-12.87%
Perf 5Y	-83.45%
Perf 10Y	-47.79%
Recom	1.00
Target Price	5.50
Prev Close	0.27
Price	0.27
Change	0.18%

Jun-23-26 08:30AM	IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow (ACCESSWIRE)
Jun-11-26 08:30AM	IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis (ACCESSWIRE)
Jun-09-26 08:30AM	Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts (ACCESSWIRE)
Jun-02-26 08:30AM	IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis (ACCESSWIRE)
May-19-26 05:30PM	IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment (ACCESSWIRE)
08:00AM	Loading…
May-15-26 08:00AM	IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference (ACCESSWIRE)
Apr-28-26 12:15PM	IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase (ACCESSWIRE)
Apr-22-26 08:30AM	IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion (ACCESSWIRE) +10.17%
Apr-20-26 08:30AM	IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia (ACCESSWIRE) -5.03%
Apr-14-26 08:30AM	IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout (ACCESSWIRE)
Apr-08-26 12:45PM	Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts (ACCESSWIRE)
Apr-07-26 08:00AM	IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease (ACCESSWIRE)
Mar-30-26 08:00AM	IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness (ACCESSWIRE)
Mar-19-26 09:00AM	IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 (ACCESSWIRE)
Mar-18-26 09:00AM	IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 (ACCESSWIRE)
07:05AM	Loading…
Mar-05-26 07:05AM	Merck KGaA (MKKGY) Lags Q4 Earnings Estimates (Zacks)
Feb-26-26 08:30AM	IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research (ACCESSWIRE)
Feb-24-26 08:49AM	IGC Pharma expands Phase 2 CALMA trial with new clinical site (TipRanks)
08:30AM	IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets (ACCESSWIRE)
Feb-23-26 08:30AM	IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial (ACCESSWIRE)
Feb-17-26 08:30AM	IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances (ACCESSWIRE)
Feb-12-26 08:30AM	IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets (ACCESSWIRE)
Feb-10-26 08:30AM	IGC Pharma Announces Equity Research Update by Alliance Global Partners (ACCESSWIRE)
Feb-09-26 08:30AM	IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center (ACCESSWIRE)
Feb-02-26 08:30AM	IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation (ACCESSWIRE)
Jan-22-26 09:00AM	IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York (ACCESSWIRE) +7.31%
Jan-12-26 09:00AM	IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia (ACCESSWIRE)
Jan-06-26 08:00AM	IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability (ACCESSWIRE)
Jan-05-26 09:00AM	IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial (ACCESSWIRE)
Dec-19-25 09:00AM	IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum (ACCESSWIRE) -10.74%
09:00AM	Loading…
Dec-15-25 09:00AM	IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines (ACCESSWIRE)
Dec-13-25 11:15AM	Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says (TipRanks)
Dec-10-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." (ACCESSWIRE) +14.77%
Dec-09-25 09:00AM	IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial (ACCESSWIRE)
Dec-02-25 09:00AM	IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease (ACCESSWIRE)
Nov-25-25 09:00AM	IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends (ACCESSWIRE)
Nov-17-25 06:00PM	IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers (GuruFocus.com) -5.03%
08:30AM	IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital (ACCESSWIRE)
Nov-14-25 05:30PM	IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Nov-13-25 05:20PM	Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
09:00AM	USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders (ACCESSWIRE)
Nov-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.35%
Nov-10-25 05:20PM	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-06-25 07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 08:52AM	IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline (ACCESSWIRE)
Oct-24-25 12:00PM	All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy (Zacks) +7.90%
10:00AM	Best Momentum Stocks to Buy for Oct. 24 (Zacks)
05:17AM	New Strong Buy Stocks for Oct. 24: IGC, ASM and More (Zacks)
Oct-22-25 09:00AM	IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" (ACCESSWIRE)
Oct-14-25 09:00AM	IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences (ACCESSWIRE) +5.96%
Oct-10-25 07:50PM	IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders (ACCESSWIRE)
Oct-07-25 09:00AM	IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease (ACCESSWIRE)
Sep-29-25 09:00AM	IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial (ACCESSWIRE) +5.61%
Sep-24-25 09:00AM	IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology (ACCESSWIRE)
Sep-22-25 09:00AM	IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial (ACCESSWIRE)
Sep-09-25 09:00AM	IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection (ACCESSWIRE)
Sep-02-25 09:00AM	IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada (ACCESSWIRE)
Aug-28-25 09:00AM	IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome (ACCESSWIRE) -5.87%
Aug-27-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." (ACCESSWIRE) +15.74%
Aug-25-25 09:00AM	IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City (ACCESSWIRE)
Aug-19-25 09:00AM	IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial (ACCESSWIRE)
Aug-14-25 05:25PM	IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 05:15PM	Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:00AM	IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 (ACCESSWIRE)
Aug-05-25 09:00AM	IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression (ACCESSWIRE)
Jul-23-25 09:00AM	IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 (ACCESSWIRE)
Jul-21-25 09:00AM	IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards (ACCESSWIRE)
Jul-10-25 03:10PM	IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection (ACCESSWIRE) +13.39%
Jun-30-25 09:00AM	IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation (ACCESSWIRE)
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-23-25 08:30AM	IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon (ACCESSWIRE)
May-30-25 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.22%
May-22-25 09:30AM	IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market (ACCESSWIRE)
May-12-25 09:30AM	IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting (ACCESSWIRE)
Apr-24-25 09:30AM	IGC Pharma Welcomes Strategic Investment from Advisors (ACCESSWIRE) +6.73%
Apr-09-25 09:35AM	IGC Pharma expands CALMA trial with addition of Butler Hospital Program (TipRanks)
Mar-17-25 09:00AM	IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida (ACCESS Newswire)
Mar-12-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" (ACCESS Newswire) +9.59%
Mar-10-25 09:00AM	IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" (ACCESS Newswire) +6.46%
Mar-04-25 09:00AM	IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection (ACCESS Newswire)
Feb-21-25 09:25AM	IGC Pharma expands Holiby line with Longevity, Renew (TipRanks)
Feb-20-25 09:00AM	IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market (ACCESS Newswire)
Feb-18-25 08:30AM	IGC Pharma Reports Third Quarter Fiscal 2025 Results (ACCESS Newswire)
Feb-11-25 08:30AM	IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) (ACCESS Newswire)
Jan-28-25 08:30AM	IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease (ACCESS Newswire)
Jan-21-25 08:30AM	IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor (ACCESS Newswire)
Jan-13-25 08:30AM	IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets (ACCESSWIRE)
Jan-08-25 08:30AM	IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy (ACCESSWIRE)
Dec-19-24 07:00PM	IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 (ACCESSWIRE)
Dec-02-24 08:30AM	IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology (ACCESSWIRE)
Nov-25-24 08:30AM	IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment (Business Wire) +5.34%
Nov-14-24 08:30AM	IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline (ACCESSWIRE)
Nov-06-24 08:30AM	IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies (ACCESSWIRE)
Oct-17-24 08:30AM	IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 (ACCESSWIRE)
Oct-03-24 09:00AM	IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge (ACCESSWIRE) -6.10%
Sep-18-24 08:00AM	IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment (Business Wire)
Sep-04-24 08:00AM	IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease (Business Wire)
Aug-26-24 07:00PM	IGC Announces Results of its 2024 Annual Stockholders Meeting (Business Wire)
Aug-22-24 09:00AM	IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease (Business Wire) -7.56%

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

FounderMr. Ram Mukunda

VPMs. Claudia Grimaldi

M.B.A.Benysh Qureshi Esq.

M.B.A.Mr. Rohit Goel CPA

Sales ManagerSusana Salgar

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PRINS RICHARD K	Director	Apr 01 '26	Option Exercise	0.00	170,000	0	1,541,251	Apr 06 04:02 PM
Mukunda Ram	CEO	Apr 01 '26	Option Exercise	0.13	656,410	84,000	4,649,088	Apr 06 04:02 PM
Mukunda Ram	CEO	Apr 01 '26	Option Exercise	0.00	49,999	0	910,751	Apr 06 04:02 PM
Moran James P	Director	Apr 01 '26	Option Exercise	0.00	130,000	0	1,235,735	Apr 06 04:02 PM
GRIMALDI CLAUDIA	PFO	Apr 01 '26	Option Exercise	0.15	238,462	36,000	1,372,714	Apr 06 04:01 PM
Mukunda Ram	CEO	Feb 03 '26	Option Exercise	0.00	50,000	0	860,752	Feb 04 05:31 PM
PRINS RICHARD K	Director	Jan 19 '26	Option Exercise	0.00	100,000	0	1,371,251	Jan 20 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

IGC

IGC Pharma Inc

Upgrade your Finviz experience